Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401778 · ClinicalTrials.gov registry record · Phase 1
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00401778 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 33 participants.
The verdict
NCT00401778, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 to evaluate the target effects of this compounds on relevant molecular pathways and on the 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) uptake of the tumor by a positron emission tomography (PET) scan at baseline and immediately prior to surgery. The safety profile of RAD001 will also be evaluated.
Interventions
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401778
The ClinicalTrials.gov registry entry for NCT00401778 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 is the first listed.
NCT00401778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401778 about?
NCT00401778 is a clinical study titled "Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)". This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 to evaluate the target effects of this compounds on relevant molecular pathways and on the 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) uptake of the tumor by a positr...
What is the current status of trial NCT00401778?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2006-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00401778?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00401778?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.